Sangamo Therapeutics is a genomic medicine company conducting research & development across four distinct but complementary technology platforms – gene therapy, cell therapy, in vivo genome editing, and in vivo genome regulation. The optionality and diversity inherent to Sangamo’s technology platform enables us to design therapeutic approaches to resolve the underlying genetic causes of disease, using whichever technology is best suited to deliver that treatment.

Sangamo is committed to translating ground-breaking science into genomic medicines that transform patients’ lives.


  • Data visibility with leading C&GT CDMOs entering data directly into PIMS
  • High data integrity platform to support streamlined tech transfers across process development, quality and external manufacturing
  • Low Total Costs of Ownership (TCO)
  • Low risk, future-proofed foundation and hub to scale and connect to growing IT architecture
  • Easy to validate
  • High data integrity – Part 11 compliant, approvals, audit trails


  • MS Excel
  • R&D-based tools